BMS, Eisai Team Up To Accelerate Development Of Solid-Tumor ADC

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

The US firm gets development and co-commercial rights to MORAb-202 for $650m up front. BMS joins AstraZeneca, Merck & Co. and Gilead in recent ADC deal-making.

Lung Cancer
BMS is partnering with Eisai on an ADC with potential in solid tumors such as lung cancer

Bristol Myers Squibb Companyexpanded its involvement in the cancer antibody-drug conjugate space on 17 June, announcing a partnership with Eisai Co., Ltd. around Phase I/II ADC MORAb-202, which is being studied in folate receptor alpha (FRɑ)-positive solid tumors. The US pharma is paying Eisai $650m up front under the deal, including $200m to cover the Japanese firm’s R&D expenses, getting rights to develop and co-commercialize the product in major geographies including the US, Europe and Asia.

The deal follows transactions in the past 12 months in which major oncology players such as Merck & Co.,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.